Research ArticleGenetics

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

See allHide authors and affiliations

Science Translational Medicine  24 Jun 2020:
Vol. 12, Issue 549, eaay6570
DOI: 10.1126/scitranslmed.aay6570

Article Information

vol. 12 no. 549

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 17, 2019
  • Resubmitted November 26, 2019
  • Accepted for publication May 26, 2020
  • .

Author Information

  1. Jonas Bovijn1,2,*,,
  2. Kristi Krebs3,*,
  3. Chia-Yen Chen4,5,6,*,,
  4. Ruth Boxall7,8,*,
  5. Jenny C. Censin1,2,
  6. Teresa Ferreira1,
  7. Sara L. Pulit1,9,10,§,
  8. Craig A. Glastonbury1,||,
  9. Samantha Laber1,2,
  10. Iona Y. Millwood7,8,
  11. Kuang Lin7,
  12. Liming Li11,
  13. Zhengming Chen7,
  14. Lili Milani3,
  15. George Davey Smith12,13,
  16. Robin G. Walters7,8,*,
  17. Reedik Mägi3,*,
  18. Benjamin M. Neale4,6,*,
  19. Cecilia M. Lindgren1,2,9,14,*, and
  20. Michael V. Holmes1,7,8,14,*,
  1. 1Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7FZ, UK.
  2. 2Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  3. 3Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu 51010, Estonia.
  4. 4Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
  5. 5Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
  6. 6Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  7. 7Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  8. 8Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
  9. 9Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA.
  10. 10Department of Genetics, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.
  11. 11Department of Epidemiology and Biostatistics, Peking University Health Science Centre, Peking University, Beijing 100191, China.
  12. 12Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol BS8 2BN, UK.
  13. 13Population Health Sciences, Bristol Medical School, University of Bristol, Barley House, Oakfield Grove, Bristol BS8 2BN, UK.
  14. 14National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, UK.
  1. Corresponding author. Email: jbovijn{at}well.ox.ac.uk (J.B.); celi{at}broadinstitute.org (C.M.L.); michael.holmes{at}ndph.ox.ac.uk (M.V.H.)
  • * These authors contributed equally to this work.

  • Present address: Biogen, Cambridge, MA 02142, USA.

  • § Present address: Vertex Pharmaceuticals, Abingdon OX14 4RW, UK.

  • || Present address: BenevolentAI, London W1T 5HD, UK

Altmetric

Article usage

Article usage: June 2020 to July 2020

AbstractFullPdf
Jun 20201913424791
Jul 2020131815281

Stay Connected to Science Translational Medicine